Regulatory Determination / Use
Drug-drug interactions are an important clinical concern. In a March 2017 Advisory Committee, briefing documents raised the possibility that oxymorphone may be used for a particular niche - patients taking multiple medications - because its metabolism did not involve the hepatic cytochrome P450 system. FDA conducted an analysis to assess whether oxymorphone’s metabolism influenced prescriber practices. Results revealed that similar proportions of patients were dispensed oxymorphone combined with other CYP modifiers relative to reference products, suggesting that drug metabolism differences did not influence prescribing behavior.
Result(s) (1)Concomitant Use of Opioid Analgesics and Cytochrome P450 (CYP) Inhibitors and Inducers
Regulatory Link(s) (1)Advisory Committee
Related Publication(s) and/or Presentation(s) (1)Publication: Concomitant Filled Prescriptions of Oxymorphone or Oxycodone with CYP3A Inhibitors and Inducers